25 XP   0   0   10

Santen Pharmaceutical Co
Buy, Hold or Sell?

Let's analyse Santen together

PenkeI guess you are interested in Santen Pharmaceutical Co. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Santen Pharmaceutical Co. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Santen Pharmaceutical Co

I send you an email if I find something interesting about Santen Pharmaceutical Co.

Quick analysis of Santen (30 sec.)










What can you expect buying and holding a share of Santen? (30 sec.)

How much money do you get?

How much money do you get?
$0.21
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
$5.33
Expected worth in 1 year
$5.62
How sure are you?
80.0%

+ What do you gain per year?

Total Gains per Share
$0.49
Return On Investment
5.2%

For what price can you sell your share?

Current Price per Share
$9.41
Expected price per share
$8.31 - $10.80
How sure are you?
50%

1. Valuation of Santen (5 min.)




Live pricePrice per Share (EOD)

$9.41

Intrinsic Value Per Share

$9.32 - $36.86

Total Value Per Share

$14.65 - $42.19

2. Growth of Santen (5 min.)




Is Santen growing?

Current yearPrevious yearGrowGrow %
How rich?$1.9b$2b-$148.6m-7.6%

How much money is Santen making?

Current yearPrevious yearGrowGrow %
Making money$45m-$13.2m$58.3m129.4%
Net Profit Margin9.3%-3.9%--

How much money comes from the company's main activities?

3. Financial Health of Santen (5 min.)




What can you expect buying and holding a share of Santen? (5 min.)

Welcome investor! Santen's management wants to use your money to grow the business. In return you get a share of Santen.

What can you expect buying and holding a share of Santen?

First you should know what it really means to hold a share of Santen. And how you can make/lose money.

Speculation

The Price per Share of Santen is $9.41. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Santen.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Santen, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $5.33. Based on the TTM, the Book Value Change Per Share is $0.07 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.04 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.05 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Santen.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.131.4%0.161.7%-0.04-0.4%0.070.8%0.101.0%
Usd Book Value Change Per Share-0.15-1.6%0.070.8%-0.04-0.4%0.030.3%0.060.7%
Usd Dividend Per Share0.101.1%0.050.6%0.050.6%0.050.5%0.040.5%
Usd Total Gains Per Share-0.05-0.5%0.121.3%0.010.1%0.080.8%0.111.1%
Usd Price Per Share9.85-8.97-8.15-13.12-15.72-
Price to Earnings Ratio18.77-14.14-13.50-27.04-40.56-
Price-to-Total Gains Ratio-204.94-195.55--2.05--134.78-44.48-
Price to Book Ratio1.85-1.70-1.52-2.60-3.81-
Price-to-Total Gains Ratio-204.94-195.55--2.05--134.78-44.48-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share9.41
Number of shares106
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.050.05
Usd Book Value Change Per Share0.070.03
Usd Total Gains Per Share0.120.08
Gains per Quarter (106 shares)13.068.16
Gains per Year (106 shares)52.2332.63
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1223042201223
2446094412456
36790146613789
4891201988249122
511115025010261155
613318030212373188
715621035414385221
817824040616398254
9200270458184110287
10222300510204122320

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%10.02.00.083.3%18.02.00.090.0%38.02.00.095.0%59.02.00.096.7%
Book Value Change Per Share3.01.00.075.0%8.04.00.066.7%13.07.00.065.0%29.011.00.072.5%43.017.01.070.5%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%61.00.00.0100.0%
Total Gains per Share3.01.00.075.0%8.04.00.066.7%14.06.00.070.0%32.08.00.080.0%52.09.00.085.2%

Fundamentals of Santen

About Santen Pharmaceutical Co

Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in phase 3 of clinical trials; and latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative which is filed for marketing approval for the treatment of glaucoma and ocular hypertension. In addition, it provides cyclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis; and diquafosol sodium for dry eye treatment. Further, the company develops olodaterol hydrochloride, a ß2 receptor agonist that is in phase 1/2a for the treatment of A dry eye treatment dry eye; sirolimus, an ophthalmic suspension which is in phase 2a for the treatment of 4 Fuchs endothelial corneal dystrophy and meibomian gland dysfunction; epinastine hydrochloride, a histamine H1 receptor antagonist filed for marketing approval for the treatment of allergic conjunctivitis; atropine sulfate, a non-selective muscarinic antagonist that is in phase 2/3 clinical trials for myopia treatment; and AFDX0250BS, an selective muscarinic M2 antagonist which is in phase 2a for the treatment of myopia. Additionally, it offers ursodeoxycholic acid that is in phase 2a of clinical trial for the treatment of presbyopia; and oxymetazoline hydrochloride, a direct-acting alpha adrenergic receptor agonist which is in phase 3 for treatment of ptosis. The company was founded in 1890 and is headquartered in Osaka, Japan.

Fundamental data was last updated by Penke on 2024-04-03 18:20:07.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Santen Pharmaceutical Co.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Santen earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Santen to the Drug Manufacturers - General industry mean.
  • A Net Profit Margin of 9.5% means that $0.10 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Santen Pharmaceutical Co:

  • The MRQ is 9.5%. The company is making a profit. +1
  • The TTM is 9.3%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ9.5%TTM9.3%+0.2%
TTM9.3%YOY-3.9%+13.2%
TTM9.3%5Y5.9%+3.4%
5Y5.9%10Y10.9%-5.0%
1.1.2. Return on Assets

Shows how efficient Santen is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Santen to the Drug Manufacturers - General industry mean.
  • 1.7% Return on Assets means that Santen generated $0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Santen Pharmaceutical Co:

  • The MRQ is 1.7%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.6%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.7%TTM1.6%+0.1%
TTM1.6%YOY-0.5%+2.2%
TTM1.6%5Y0.9%+0.7%
5Y0.9%10Y1.7%-0.7%
1.1.3. Return on Equity

Shows how efficient Santen is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Santen to the Drug Manufacturers - General industry mean.
  • 2.5% Return on Equity means Santen generated $0.02 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Santen Pharmaceutical Co:

  • The MRQ is 2.5%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.3%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ2.5%TTM2.3%+0.2%
TTM2.3%YOY-0.7%+3.0%
TTM2.3%5Y1.3%+1.0%
5Y1.3%10Y2.2%-1.0%

1.2. Operating Efficiency of Santen Pharmaceutical Co.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Santen is operating .

  • Measures how much profit Santen makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Santen to the Drug Manufacturers - General industry mean.
  • An Operating Margin of 13.2% means the company generated $0.13  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Santen Pharmaceutical Co:

  • The MRQ is 13.2%. The company is operating less efficient.
  • The TTM is 13.9%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ13.2%TTM13.9%-0.6%
TTM13.9%YOY-0.7%+14.6%
TTM13.9%5Y9.7%+4.1%
5Y9.7%10Y16.3%-6.6%
1.2.2. Operating Ratio

Measures how efficient Santen is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • An Operation Ratio of 0.86 means that the operating costs are $0.86 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Santen Pharmaceutical Co:

  • The MRQ is 0.856. The company is less efficient in keeping operating costs low.
  • The TTM is 0.856. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.856TTM0.856+0.001
TTM0.856YOY1.011-0.155
TTM0.8565Y0.904-0.048
5Y0.90410Y0.840+0.064

1.3. Liquidity of Santen Pharmaceutical Co.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Santen is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A Current Ratio of 2.46 means the company has $2.46 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Santen Pharmaceutical Co:

  • The MRQ is 2.456. The company is able to pay all its short-term debts. +1
  • The TTM is 2.543. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.456TTM2.543-0.086
TTM2.543YOY2.631-0.088
TTM2.5435Y2.885-0.342
5Y2.88510Y2.987-0.103
1.3.2. Quick Ratio

Measures if Santen is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Santen to the Drug Manufacturers - General industry mean.
  • A Quick Ratio of 1.86 means the company can pay off $1.86 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Santen Pharmaceutical Co:

  • The MRQ is 1.855. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.928. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.855TTM1.928-0.073
TTM1.928YOY2.054-0.126
TTM1.9285Y2.256-0.329
5Y2.25610Y2.421-0.164

1.4. Solvency of Santen Pharmaceutical Co.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Santen assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Santen to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.30 means that Santen assets are financed with 30.3% credit (debt) and the remaining percentage (100% - 30.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Santen Pharmaceutical Co:

  • The MRQ is 0.303. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.292. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.303TTM0.292+0.011
TTM0.292YOY0.271+0.021
TTM0.2925Y0.261+0.031
5Y0.26110Y0.257+0.004
1.4.2. Debt to Equity Ratio

Measures if Santen is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Santen to the Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 43.5% means that company has $0.43 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Santen Pharmaceutical Co:

  • The MRQ is 0.435. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.412. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.435TTM0.412+0.023
TTM0.412YOY0.371+0.041
TTM0.4125Y0.354+0.059
5Y0.35410Y0.348+0.006

2. Market Valuation of Santen Pharmaceutical Co

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Santen generates.

  • Above 15 is considered overpriced but always compare Santen to the Drug Manufacturers - General industry mean.
  • A PE ratio of 18.77 means the investor is paying $18.77 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Santen Pharmaceutical Co:

  • The EOD is 17.931. Based on the earnings, the company is fair priced.
  • The MRQ is 18.769. Based on the earnings, the company is fair priced.
  • The TTM is 14.145. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD17.931MRQ18.769-0.838
MRQ18.769TTM14.145+4.625
TTM14.145YOY13.502+0.642
TTM14.1455Y27.043-12.899
5Y27.04310Y40.556-13.512
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Santen Pharmaceutical Co:

  • The EOD is 4.370. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 4.574. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is -68.221. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD4.370MRQ4.574-0.204
MRQ4.574TTM-68.221+72.795
TTM-68.221YOY-79.558+11.337
TTM-68.2215Y-36.161-32.060
5Y-36.16110Y-0.159-36.003
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Santen is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 1.85 means the investor is paying $1.85 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Santen Pharmaceutical Co:

  • The EOD is 1.765. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.847. Based on the equity, the company is underpriced. +1
  • The TTM is 1.700. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.765MRQ1.847-0.083
MRQ1.847TTM1.700+0.147
TTM1.700YOY1.522+0.178
TTM1.7005Y2.600-0.900
5Y2.60010Y3.809-1.209
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Santen Pharmaceutical Co compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.1520.071-314%-0.039-74%0.029-626%0.063-340%
Book Value Per Share--5.3325.273+1%5.3550%5.109+4%4.513+18%
Current Ratio--2.4562.543-3%2.631-7%2.885-15%2.987-18%
Debt To Asset Ratio--0.3030.292+4%0.271+12%0.261+16%0.257+18%
Debt To Equity Ratio--0.4350.412+5%0.371+17%0.354+23%0.348+25%
Dividend Per Share--0.1030.052+97%0.052+98%0.048+115%0.044+136%
Eps--0.1310.163-19%-0.038+129%0.072+82%0.099+33%
Free Cash Flow Per Share--0.5380.256+110%0.032+1590%0.110+389%0.094+471%
Free Cash Flow To Equity Per Share--0.3300.078+324%-0.045+114%0.021+1498%0.028+1097%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--36.856--------
Intrinsic Value_10Y_min--9.316--------
Intrinsic Value_1Y_max--0.970--------
Intrinsic Value_1Y_min--0.475--------
Intrinsic Value_3Y_max--4.989--------
Intrinsic Value_3Y_min--1.832--------
Intrinsic Value_5Y_max--11.511--------
Intrinsic Value_5Y_min--3.624--------
Market Cap3418229625.280-5%3578061828.8003309240507.545+8%3194904030.075+12%5187942010.265-31%6368946339.320-44%
Net Profit Margin--0.0950.093+2%-0.039+141%0.059+61%0.109-13%
Operating Margin--0.1320.139-5%-0.007+105%0.097+36%0.163-19%
Operating Ratio--0.8560.856+0%1.011-15%0.904-5%0.840+2%
Pb Ratio1.765-5%1.8471.700+9%1.522+21%2.600-29%3.809-51%
Pe Ratio17.931-5%18.76914.145+33%13.502+39%27.043-31%40.556-54%
Price Per Share9.410-5%9.8508.968+10%8.150+21%13.124-25%15.724-37%
Price To Free Cash Flow Ratio4.370-5%4.574-68.221+1591%-79.558+1839%-36.161+891%-0.159+103%
Price To Total Gains Ratio-195.786+4%-204.941195.547-205%-2.048-99%-134.779-34%44.479-561%
Quick Ratio--1.8551.928-4%2.054-10%2.256-18%2.421-23%
Return On Assets--0.0170.016+5%-0.005+131%0.009+83%0.017+3%
Return On Equity--0.0250.023+7%-0.007+130%0.013+94%0.022+9%
Total Gains Per Share---0.0480.123-139%0.013-468%0.077-162%0.107-145%
Usd Book Value--1936896000.0001946675250.000-1%2095325375.000-8%2003775150.000-3%1807339137.500+7%
Usd Book Value Change Per Share---0.1520.071-314%-0.039-74%0.029-626%0.063-340%
Usd Book Value Per Share--5.3325.273+1%5.3550%5.109+4%4.513+18%
Usd Dividend Per Share--0.1030.052+97%0.052+98%0.048+115%0.044+136%
Usd Eps--0.1310.163-19%-0.038+129%0.072+82%0.099+33%
Usd Free Cash Flow--195546000.00093210000.000+110%11938875.000+1538%42121625.000+364%37156275.000+426%
Usd Free Cash Flow Per Share--0.5380.256+110%0.032+1590%0.110+389%0.094+471%
Usd Free Cash Flow To Equity Per Share--0.3300.078+324%-0.045+114%0.021+1498%0.028+1097%
Usd Market Cap3418229625.280-5%3578061828.8003309240507.545+8%3194904030.075+12%5187942010.265-31%6368946339.320-44%
Usd Price Per Share9.410-5%9.8508.968+10%8.150+21%13.124-25%15.724-37%
Usd Profit--47658000.00045058000.000+6%-13247000.000+128%25356175.000+88%38795737.500+23%
Usd Revenue--500675500.000490886500.000+2%439143250.000+14%429033475.000+17%376055712.500+33%
Usd Total Gains Per Share---0.0480.123-139%0.013-468%0.077-162%0.107-145%
 EOD+5 -3MRQTTM+17 -18YOY+19 -165Y+21 -1410Y+19 -16

3.2. Fundamental Score

Let's check the fundamental score of Santen Pharmaceutical Co based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1517.931
Price to Book Ratio (EOD)Between0-11.765
Net Profit Margin (MRQ)Greater than00.095
Operating Margin (MRQ)Greater than00.132
Quick Ratio (MRQ)Greater than11.855
Current Ratio (MRQ)Greater than12.456
Debt to Asset Ratio (MRQ)Less than10.303
Debt to Equity Ratio (MRQ)Less than10.435
Return on Equity (MRQ)Greater than0.150.025
Return on Assets (MRQ)Greater than0.050.017
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of Santen Pharmaceutical Co based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.400
Ma 20Greater thanMa 509.462
Ma 50Greater thanMa 1009.778
Ma 100Greater thanMa 2009.767
OpenGreater thanClose9.410
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in JPY. All numbers in thousands.

Summary
Total Assets427,820,000
Total Liabilities129,836,000
Total Stockholder Equity298,720,000
 As reported
Total Liabilities 129,836,000
Total Stockholder Equity+ 298,720,000
Total Assets = 427,820,000

Assets

Total Assets427,820,000
Total Current Assets224,606,000
Long-term Assets203,214,000
Total Current Assets
Cash And Cash Equivalents 82,030,000
Short-term Investments 1,328,000
Net Receivables 84,940,000
Inventory 46,923,000
Other Current Assets 9,385,000
Total Current Assets  (as reported)224,606,000
Total Current Assets  (calculated)224,606,000
+/-0
Long-term Assets
Property Plant Equipment 68,451,000
Intangible Assets 91,460,000
Long-term Assets Other 7,351,000
Long-term Assets  (as reported)203,214,000
Long-term Assets  (calculated)167,262,000
+/- 35,952,000

Liabilities & Shareholders' Equity

Total Current Liabilities91,438,000
Long-term Liabilities38,398,000
Total Stockholder Equity298,720,000
Total Current Liabilities
Accounts payable 45,121,000
Other Current Liabilities 46,317,000
Total Current Liabilities  (as reported)91,438,000
Total Current Liabilities  (calculated)91,438,000
+/-0
Long-term Liabilities
Long-term Liabilities Other 1,494,000
Long-term Liabilities  (as reported)38,398,000
Long-term Liabilities  (calculated)1,494,000
+/- 36,904,000
Total Stockholder Equity
Common Stock8,769,000
Retained Earnings 253,167,000
Accumulated Other Comprehensive Income 43,674,000
Other Stockholders Equity -6,890,000
Total Stockholder Equity (as reported)298,720,000
Total Stockholder Equity (calculated)298,720,000
+/-0
Other
Capital Stock8,769,000
Cash and Short Term Investments 83,358,000
Common Stock Shares Outstanding 354,921
Liabilities and Stockholders Equity 427,820,000
Net Debt -48,407,000
Net Invested Capital 298,720,000
Net Working Capital 133,168,000
Short Long Term Debt Total 33,623,000



Balance Sheet

Currency in JPY. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-30
> Total Assets 
0
0
151,012,000
0
164,520,000
161,507,000
166,878,000
159,810,000
167,378,000
166,167,000
184,801,000
182,007,000
188,459,000
187,577,000
198,801,000
188,884,000
184,746,000
184,610,000
199,639,000
203,555,000
211,689,000
218,748,000
231,104,000
256,502,000
261,630,000
278,019,000
304,200,000
301,447,000
352,080,000
359,849,000
355,399,000
328,782,000
323,555,000
321,249,000
322,778,000
325,577,000
374,180,000
378,375,000
388,463,000
378,420,000
400,030,000
388,284,000
391,186,000
386,304,000
397,073,000
407,712,000
408,768,000
409,586,000
420,021,000
413,087,000
402,353,000
397,096,000
420,435,000
429,598,000
459,976,000
461,284,000
426,580,000
420,141,000
421,179,000
416,528,000
426,984,000
427,820,000
427,820,000426,984,000416,528,000421,179,000420,141,000426,580,000461,284,000459,976,000429,598,000420,435,000397,096,000402,353,000413,087,000420,021,000409,586,000408,768,000407,712,000397,073,000386,304,000391,186,000388,284,000400,030,000378,420,000388,463,000378,375,000374,180,000325,577,000322,778,000321,249,000323,555,000328,782,000355,399,000359,849,000352,080,000301,447,000304,200,000278,019,000261,630,000256,502,000231,104,000218,748,000211,689,000203,555,000199,639,000184,610,000184,746,000188,884,000198,801,000187,577,000188,459,000182,007,000184,801,000166,167,000167,378,000159,810,000166,878,000161,507,000164,520,0000151,012,00000
   > Total Current Assets 
0
0
101,053,000
0
114,010,000
112,159,000
118,832,000
113,435,000
118,927,000
118,987,000
137,668,000
135,388,000
142,285,000
129,130,000
140,288,000
128,962,000
123,909,000
124,220,000
132,582,000
130,934,000
139,340,000
143,802,000
156,006,000
181,933,000
130,321,000
139,436,000
150,672,000
147,606,000
199,171,000
197,993,000
194,739,000
173,110,000
156,626,000
151,137,000
157,011,000
158,752,000
169,832,000
170,186,000
183,367,000
174,440,000
186,941,000
188,851,000
194,742,000
188,328,000
202,428,000
207,411,000
218,556,000
209,053,000
187,083,000
183,892,000
206,231,000
197,007,000
211,182,000
209,004,000
229,426,000
218,679,000
206,850,000
204,790,000
213,326,000
203,266,000
215,975,000
224,606,000
224,606,000215,975,000203,266,000213,326,000204,790,000206,850,000218,679,000229,426,000209,004,000211,182,000197,007,000206,231,000183,892,000187,083,000209,053,000218,556,000207,411,000202,428,000188,328,000194,742,000188,851,000186,941,000174,440,000183,367,000170,186,000169,832,000158,752,000157,011,000151,137,000156,626,000173,110,000194,739,000197,993,000199,171,000147,606,000150,672,000139,436,000130,321,000181,933,000156,006,000143,802,000139,340,000130,934,000132,582,000124,220,000123,909,000128,962,000140,288,000129,130,000142,285,000135,388,000137,668,000118,987,000118,927,000113,435,000118,832,000112,159,000114,010,0000101,053,00000
       Cash And Cash Equivalents 
0
0
37,117,000
0
49,351,000
49,855,000
56,677,000
49,581,000
55,435,000
52,843,000
65,558,000
63,455,000
69,991,000
57,614,000
66,235,000
54,029,000
48,792,000
47,310,000
50,884,000
45,361,000
52,786,000
54,625,000
63,509,000
92,716,000
47,072,000
58,303,000
65,923,000
56,161,000
108,011,000
104,062,000
99,798,000
74,516,000
58,343,000
48,100,000
53,297,000
48,952,000
61,846,000
60,048,000
69,283,000
57,483,000
75,237,000
75,394,000
70,796,000
67,798,000
84,972,000
82,595,000
91,430,000
82,346,000
58,745,000
52,913,000
62,888,000
54,699,000
76,036,000
67,833,000
83,014,000
68,575,000
69,140,000
61,220,000
57,903,000
45,510,000
64,728,000
82,030,000
82,030,00064,728,00045,510,00057,903,00061,220,00069,140,00068,575,00083,014,00067,833,00076,036,00054,699,00062,888,00052,913,00058,745,00082,346,00091,430,00082,595,00084,972,00067,798,00070,796,00075,394,00075,237,00057,483,00069,283,00060,048,00061,846,00048,952,00053,297,00048,100,00058,343,00074,516,00099,798,000104,062,000108,011,00056,161,00065,923,00058,303,00047,072,00092,716,00063,509,00054,625,00052,786,00045,361,00050,884,00047,310,00048,792,00054,029,00066,235,00057,614,00069,991,00063,455,00065,558,00052,843,00055,435,00049,581,00056,677,00049,855,00049,351,000037,117,00000
       Short-term Investments 
0
0
11,396,000
0
10,498,000
9,598,000
8,998,000
8,998,000
8,913,000
11,526,000
13,332,000
12,126,000
13,450,000
12,940,000
12,739,000
12,734,000
13,208,000
12,813,000
11,007,000
11,510,000
12,310,000
12,410,000
13,111,000
8,606,000
6,503,000
1,201,000
187,000
335,000
342,000
544,000
234,000
306,000
187,000
351,000
333,000
726,000
843,000
284,000
472,000
355,000
335,000
256,000
267,000
395,000
429,000
462,000
452,000
542,000
572,000
579,000
527,000
401,000
367,000
453,000
1,293,000
956,000
800,000
1,098,000
774,000
1,584,000
1,631,000
1,328,000
1,328,0001,631,0001,584,000774,0001,098,000800,000956,0001,293,000453,000367,000401,000527,000579,000572,000542,000452,000462,000429,000395,000267,000256,000335,000355,000472,000284,000843,000726,000333,000351,000187,000306,000234,000544,000342,000335,000187,0001,201,0006,503,0008,606,00013,111,00012,410,00012,310,00011,510,00011,007,00012,813,00013,208,00012,734,00012,739,00012,940,00013,450,00012,126,00013,332,00011,526,0008,913,0008,998,0008,998,0009,598,00010,498,000011,396,00000
       Net Receivables 
0
0
37,952,000
0
39,399,000
38,960,000
37,434,000
39,046,000
39,308,000
39,374,000
40,966,000
40,246,000
40,985,000
41,340,000
39,844,000
41,732,000
41,063,000
43,220,000
45,720,000
48,627,000
49,592,000
54,116,000
54,432,000
51,918,000
54,548,000
58,136,000
61,701,000
65,224,000
65,554,000
68,708,000
65,998,000
69,086,000
66,687,000
73,561,000
70,970,000
77,079,000
74,837,000
78,515,000
78,654,000
80,570,000
76,235,000
78,720,000
84,618,000
82,349,000
78,342,000
87,222,000
86,999,000
82,174,000
81,321,000
86,334,000
95,992,000
94,039,000
86,250,000
93,359,000
99,591,000
99,690,000
87,683,000
95,335,000
107,225,000
103,831,000
93,486,000
84,940,000
84,940,00093,486,000103,831,000107,225,00095,335,00087,683,00099,690,00099,591,00093,359,00086,250,00094,039,00095,992,00086,334,00081,321,00082,174,00086,999,00087,222,00078,342,00082,349,00084,618,00078,720,00076,235,00080,570,00078,654,00078,515,00074,837,00077,079,00070,970,00073,561,00066,687,00069,086,00065,998,00068,708,00065,554,00065,224,00061,701,00058,136,00054,548,00051,918,00054,432,00054,116,00049,592,00048,627,00045,720,00043,220,00041,063,00041,732,00039,844,00041,340,00040,985,00040,246,00040,966,00039,374,00039,308,00039,046,00037,434,00038,960,00039,399,000037,952,00000
       Other Current Assets 
0
0
2,354,000
0
2,352,000
1,874,000
2,101,000
2,103,000
1,917,000
1,950,000
3,110,000
3,851,000
2,439,000
3,008,000
3,521,000
3,662,000
3,578,000
2,957,000
4,024,000
5,054,000
4,750,000
4,370,000
4,924,000
4,512,000
3,548,000
3,458,000
2,728,000
3,898,000
3,253,000
2,176,000
3,713,000
3,716,000
4,625,000
2,920,000
3,909,000
4,963,000
4,243,000
3,886,000
4,322,000
4,217,000
3,297,000
3,399,000
3,826,000
4,048,000
5,033,000
4,095,000
4,393,000
5,328,000
6,334,000
6,153,000
5,249,000
7,197,000
8,218,000
8,068,000
8,387,000
9,910,000
10,127,000
9,827,000
8,072,000
10,113,000
10,561,000
9,385,000
9,385,00010,561,00010,113,0008,072,0009,827,00010,127,0009,910,0008,387,0008,068,0008,218,0007,197,0005,249,0006,153,0006,334,0005,328,0004,393,0004,095,0005,033,0004,048,0003,826,0003,399,0003,297,0004,217,0004,322,0003,886,0004,243,0004,963,0003,909,0002,920,0004,625,0003,716,0003,713,0002,176,0003,253,0003,898,0002,728,0003,458,0003,548,0004,512,0004,924,0004,370,0004,750,0005,054,0004,024,0002,957,0003,578,0003,662,0003,521,0003,008,0002,439,0003,851,0003,110,0001,950,0001,917,0002,103,0002,101,0001,874,0002,352,00002,354,00000
   > Long-term Assets 
0
0
49,959,000
0
50,510,000
49,348,000
48,046,000
46,375,000
48,451,000
47,180,000
47,133,000
46,619,000
46,174,000
58,447,000
58,513,000
59,922,000
60,837,000
60,387,000
67,055,000
72,619,000
72,348,000
74,946,000
75,097,000
74,567,000
131,309,000
138,581,000
153,528,000
153,841,000
152,909,000
161,856,000
160,660,000
155,672,000
166,928,000
170,112,000
165,767,000
166,825,000
204,348,000
208,189,000
205,095,000
203,981,000
213,089,000
199,433,000
196,444,000
197,976,000
194,645,000
200,302,000
190,212,000
200,533,000
232,938,000
229,195,000
196,122,000
200,089,000
209,253,000
220,594,000
230,551,000
242,605,000
219,730,000
215,351,000
207,853,000
213,262,000
211,009,000
203,214,000
203,214,000211,009,000213,262,000207,853,000215,351,000219,730,000242,605,000230,551,000220,594,000209,253,000200,089,000196,122,000229,195,000232,938,000200,533,000190,212,000200,302,000194,645,000197,976,000196,444,000199,433,000213,089,000203,981,000205,095,000208,189,000204,348,000166,825,000165,767,000170,112,000166,928,000155,672,000160,660,000161,856,000152,909,000153,841,000153,528,000138,581,000131,309,00074,567,00075,097,00074,946,00072,348,00072,619,00067,055,00060,387,00060,837,00059,922,00058,513,00058,447,00046,174,00046,619,00047,133,00047,180,00048,451,00046,375,00048,046,00049,348,00050,510,000049,959,00000
       Property Plant Equipment 
0
0
28,664,000
0
27,976,000
27,141,000
26,574,000
25,863,000
25,376,000
25,159,000
24,956,000
25,117,000
24,827,000
25,297,000
25,523,000
25,240,000
25,928,000
26,098,000
27,420,000
28,167,000
28,186,000
28,118,000
27,628,000
27,313,000
27,731,000
28,578,000
29,104,000
29,281,000
28,950,000
29,257,000
27,991,000
28,165,000
28,521,000
29,010,000
28,550,000
28,602,000
29,393,000
29,671,000
29,706,000
30,614,000
31,498,000
31,035,000
31,699,000
39,144,000
38,291,000
39,211,000
35,601,000
35,735,000
36,219,000
35,648,000
39,489,000
41,644,000
49,082,000
51,343,000
56,287,000
61,185,000
65,609,000
65,558,000
66,173,000
68,425,000
69,487,000
68,451,000
68,451,00069,487,00068,425,00066,173,00065,558,00065,609,00061,185,00056,287,00051,343,00049,082,00041,644,00039,489,00035,648,00036,219,00035,735,00035,601,00039,211,00038,291,00039,144,00031,699,00031,035,00031,498,00030,614,00029,706,00029,671,00029,393,00028,602,00028,550,00029,010,00028,521,00028,165,00027,991,00029,257,00028,950,00029,281,00029,104,00028,578,00027,731,00027,313,00027,628,00028,118,00028,186,00028,167,00027,420,00026,098,00025,928,00025,240,00025,523,00025,297,00024,827,00025,117,00024,956,00025,159,00025,376,00025,863,00026,574,00027,141,00027,976,000028,664,00000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
6,199,000
5,801,000
6,179,000
5,378,000
5,309,000
5,936,000
6,065,000
6,285,000
6,252,000
6,297,000
5,930,000
5,741,000
5,846,000
0
0
0
0
0
0
0
0
29,917,000
0
0
0
17,088,220
0
0
0
22,713,000
0
0
0
0
0
0
0
0
0
0
0
13,715,000
0
0
0
7,385,000
0
0
0
0007,385,00000013,715,0000000000000022,713,00000017,088,22000029,917,000000000005,846,0005,741,0005,930,0006,297,0006,252,0006,285,0006,065,0005,936,0005,309,0005,378,0006,179,0005,801,0006,199,0000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
33,755,000
32,013,000
34,046,000
34,209,000
27,980,176
29,608,339
47,421,475
43,797,000
33,415,000
31,863,000
29,846,000
29,274,000
34,378,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000034,378,00029,274,00029,846,00031,863,00033,415,00043,797,00047,421,47529,608,33927,980,17634,209,00034,046,00032,013,00033,755,000000000000000000000000000000000000
       Intangible Assets 
0
0
1,548,000
0
1,306,000
1,221,000
1,230,000
1,153,000
1,043,000
996,000
991,000
901,000
965,000
7,173,000
7,073,000
7,577,000
6,980,000
7,197,000
8,187,000
8,546,000
9,164,000
9,384,000
10,288,000
9,984,000
65,464,000
70,143,000
84,433,000
84,705,000
82,797,000
82,618,000
83,681,000
80,591,000
100,543,000
105,247,000
102,807,000
101,974,000
138,570,000
140,343,000
134,495,000
134,840,000
135,506,000
132,725,000
131,110,000
127,243,000
125,090,000
124,493,000
119,850,000
123,720,000
148,021,000
150,786,000
112,876,000
113,322,000
115,482,000
125,234,000
130,217,000
134,914,000
103,081,000
100,610,000
96,309,000
97,083,000
94,832,000
91,460,000
91,460,00094,832,00097,083,00096,309,000100,610,000103,081,000134,914,000130,217,000125,234,000115,482,000113,322,000112,876,000150,786,000148,021,000123,720,000119,850,000124,493,000125,090,000127,243,000131,110,000132,725,000135,506,000134,840,000134,495,000140,343,000138,570,000101,974,000102,807,000105,247,000100,543,00080,591,00083,681,00082,618,00082,797,00084,705,00084,433,00070,143,00065,464,0009,984,00010,288,0009,384,0009,164,0008,546,0008,187,0007,197,0006,980,0007,577,0007,073,0007,173,000965,000901,000991,000996,0001,043,0001,153,0001,230,0001,221,0001,306,00001,548,00000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,000
2,000
2,000
1,000
2,000
1,000
2,000
2,000
2,000
0
0
0
0
0
0
1,000
2,100,000
2,397,000
2,203,000
2,176,000
1,813,783
1,000
-1,000
2,288,000
2,258,000
1,772,000
1,743,000
1,990,000
-1,000
2,100,000
2,298,000
2,446,000
2,801,000
2,824,000
3,015,000
2,753,000
2,784,000
-1,000
3,327,000
3,160,000
3,032,000
0
2,947,000
0
0
002,947,00003,032,0003,160,0003,327,000-1,0002,784,0002,753,0003,015,0002,824,0002,801,0002,446,0002,298,0002,100,000-1,0001,990,0001,743,0001,772,0002,258,0002,288,000-1,0001,0001,813,7832,176,0002,203,0002,397,0002,100,0001,0000000002,0002,0002,0001,0002,0001,0002,0002,0003,00000000000000000000
> Total Liabilities 
0
0
25,644,000
0
29,127,000
25,693,000
29,275,000
22,368,000
25,685,000
22,161,000
28,397,000
23,843,000
26,303,000
25,793,000
33,940,000
24,202,000
30,225,000
27,705,000
34,508,000
35,056,000
40,164,000
40,333,000
49,896,000
75,735,000
73,430,000
82,505,000
92,421,000
84,949,000
101,181,000
101,133,000
95,390,000
72,528,000
68,490,000
67,283,000
68,894,000
64,941,000
102,382,000
97,153,000
100,906,000
89,133,000
95,433,000
89,515,000
98,614,000
96,447,000
101,881,000
103,899,000
106,208,000
103,762,000
104,387,000
98,357,000
95,303,000
86,055,000
101,406,000
108,823,000
123,132,000
118,376,000
117,165,000
119,877,000
127,882,000
116,309,000
120,530,000
129,836,000
129,836,000120,530,000116,309,000127,882,000119,877,000117,165,000118,376,000123,132,000108,823,000101,406,00086,055,00095,303,00098,357,000104,387,000103,762,000106,208,000103,899,000101,881,00096,447,00098,614,00089,515,00095,433,00089,133,000100,906,00097,153,000102,382,00064,941,00068,894,00067,283,00068,490,00072,528,00095,390,000101,133,000101,181,00084,949,00092,421,00082,505,00073,430,00075,735,00049,896,00040,333,00040,164,00035,056,00034,508,00027,705,00030,225,00024,202,00033,940,00025,793,00026,303,00023,843,00028,397,00022,161,00025,685,00022,368,00029,275,00025,693,00029,127,000025,644,00000
   > Total Current Liabilities 
0
0
22,439,000
0
25,322,000
21,632,000
25,286,000
18,279,000
21,588,000
18,018,000
24,104,000
19,951,000
22,293,000
19,526,000
27,425,000
17,569,000
23,671,000
21,149,000
27,011,000
25,111,000
29,218,000
29,556,000
39,093,000
64,922,000
62,533,000
43,228,000
56,340,000
50,493,000
70,746,000
71,168,000
73,230,000
49,029,000
50,322,000
50,678,000
53,434,000
50,287,000
55,793,000
55,544,000
62,201,000
48,650,000
51,785,000
48,679,000
60,663,000
52,812,000
59,583,000
58,954,000
67,597,000
62,337,000
65,732,000
62,020,000
78,549,000
68,158,000
75,254,000
80,893,000
95,821,000
88,085,000
70,994,000
74,941,000
89,504,000
76,192,000
81,083,000
91,438,000
91,438,00081,083,00076,192,00089,504,00074,941,00070,994,00088,085,00095,821,00080,893,00075,254,00068,158,00078,549,00062,020,00065,732,00062,337,00067,597,00058,954,00059,583,00052,812,00060,663,00048,679,00051,785,00048,650,00062,201,00055,544,00055,793,00050,287,00053,434,00050,678,00050,322,00049,029,00073,230,00071,168,00070,746,00050,493,00056,340,00043,228,00062,533,00064,922,00039,093,00029,556,00029,218,00025,111,00027,011,00021,149,00023,671,00017,569,00027,425,00019,526,00022,293,00019,951,00024,104,00018,018,00021,588,00018,279,00025,286,00021,632,00025,322,000022,439,00000
       Short-term Debt 
0
0
655,000
0
841,000
765,000
543,000
544,000
260,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
35,000,000
35,000,000
11,767,000
0
0
0
0
0
0
0
0
16,963,000
0
0
0
3,140,952
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,056,000
0
0
0
0003,056,00000000000000000000003,140,95200016,963,0000000000011,767,00035,000,00035,000,00000000000000000260,000544,000543,000765,000841,0000655,00000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16,963,000
0
0
0
3,140,952
0
0
0
500,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000500,0000003,140,95200016,963,0000000000000000000000000000000000000
       Accounts payable 
0
0
13,432,000
0
12,486,000
11,807,000
13,536,000
12,525,000
12,570,000
12,659,000
14,475,000
13,675,000
12,961,000
13,365,000
17,083,000
11,933,000
15,009,000
7,524,000
9,266,000
9,627,000
10,197,000
10,915,000
14,270,000
15,498,000
7,429,000
11,052,000
20,250,000
21,593,000
22,901,000
25,050,000
24,504,000
24,260,000
23,745,000
22,466,000
23,937,000
23,728,000
26,431,000
24,742,000
29,743,000
27,118,000
28,425,000
27,982,000
32,079,000
27,189,000
31,411,000
30,628,000
32,578,000
33,815,000
32,507,000
30,192,000
38,106,000
33,743,000
37,810,000
38,292,000
41,185,000
40,128,000
37,178,000
41,590,000
44,945,000
41,330,000
43,878,000
45,121,000
45,121,00043,878,00041,330,00044,945,00041,590,00037,178,00040,128,00041,185,00038,292,00037,810,00033,743,00038,106,00030,192,00032,507,00033,815,00032,578,00030,628,00031,411,00027,189,00032,079,00027,982,00028,425,00027,118,00029,743,00024,742,00026,431,00023,728,00023,937,00022,466,00023,745,00024,260,00024,504,00025,050,00022,901,00021,593,00020,250,00011,052,0007,429,00015,498,00014,270,00010,915,00010,197,0009,627,0009,266,0007,524,00015,009,00011,933,00017,083,00013,365,00012,961,00013,675,00014,475,00012,659,00012,570,00012,525,00013,536,00011,807,00012,486,000013,432,00000
       Other Current Liabilities 
0
0
1,530,000
0
2,123,000
2,621,000
1,821,000
2,668,000
1,710,000
5,359,000
9,629,000
6,276,000
9,332,000
6,161,000
10,342,000
5,636,000
8,662,000
13,625,000
17,745,000
15,484,000
19,021,000
18,641,000
24,823,000
3,696,000
3,343,000
5,174,000
36,090,000
28,900,000
47,845,000
46,118,000
48,726,000
24,769,000
26,577,000
28,212,000
29,497,000
26,559,000
29,362,000
30,802,000
32,458,000
21,532,000
23,360,000
20,697,000
28,584,000
25,623,000
28,172,000
28,326,000
35,019,000
28,522,000
33,225,000
31,828,000
40,443,000
34,415,000
37,444,000
42,601,000
54,636,000
47,957,000
33,816,000
33,351,000
44,559,000
34,862,000
37,205,000
46,317,000
46,317,00037,205,00034,862,00044,559,00033,351,00033,816,00047,957,00054,636,00042,601,00037,444,00034,415,00040,443,00031,828,00033,225,00028,522,00035,019,00028,326,00028,172,00025,623,00028,584,00020,697,00023,360,00021,532,00032,458,00030,802,00029,362,00026,559,00029,497,00028,212,00026,577,00024,769,00048,726,00046,118,00047,845,00028,900,00036,090,0005,174,0003,343,0003,696,00024,823,00018,641,00019,021,00015,484,00017,745,00013,625,0008,662,0005,636,00010,342,0006,161,0009,332,0006,276,0009,629,0005,359,0001,710,0002,668,0001,821,0002,621,0002,123,00001,530,00000
   > Long-term Liabilities 
0
0
3,205,000
0
3,805,000
4,061,000
3,989,000
4,089,000
4,097,000
4,143,000
4,293,000
3,892,000
4,010,000
6,267,000
6,515,000
6,633,000
6,554,000
6,556,000
7,497,000
9,945,000
10,946,000
10,777,000
10,803,000
10,813,000
10,897,000
39,277,000
36,081,000
34,456,000
30,435,000
29,965,000
22,160,000
23,499,000
18,168,000
16,605,000
15,460,000
14,654,000
46,589,000
41,609,000
38,705,000
40,483,000
43,648,000
40,836,000
37,951,000
43,635,000
42,298,000
44,945,000
38,611,000
41,425,000
38,655,000
36,337,000
16,754,000
17,897,000
26,152,000
27,930,000
27,311,000
30,291,000
46,171,000
44,936,000
38,378,000
40,117,000
39,447,000
38,398,000
38,398,00039,447,00040,117,00038,378,00044,936,00046,171,00030,291,00027,311,00027,930,00026,152,00017,897,00016,754,00036,337,00038,655,00041,425,00038,611,00044,945,00042,298,00043,635,00037,951,00040,836,00043,648,00040,483,00038,705,00041,609,00046,589,00014,654,00015,460,00016,605,00018,168,00023,499,00022,160,00029,965,00030,435,00034,456,00036,081,00039,277,00010,897,00010,813,00010,803,00010,777,00010,946,0009,945,0007,497,0006,556,0006,554,0006,633,0006,515,0006,267,0004,010,0003,892,0004,293,0004,143,0004,097,0004,089,0003,989,0004,061,0003,805,00003,205,00000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16,605,000
7,841,000
14,654,000
46,588,000
32,473,269
26,983,215
53,204,100
43,648,000
40,836,000
34,388,000
43,635,000
42,298,000
44,945,000
32,009,000
41,425,000
38,655,000
36,337,000
9,520,000
17,897,000
26,152,000
27,930,000
8,345,000
30,291,000
46,171,000
44,936,000
0
40,117,000
0
0
0040,117,000044,936,00046,171,00030,291,0008,345,00027,930,00026,152,00017,897,0009,520,00036,337,00038,655,00041,425,00032,009,00044,945,00042,298,00043,635,00034,388,00040,836,00043,648,00053,204,10026,983,21532,473,26946,588,00014,654,0007,841,00016,605,000000000000000000000000000000000000
> Total Stockholder Equity
0
0
125,368,000
0
135,393,000
135,814,000
137,603,000
137,442,000
141,693,000
144,006,000
156,404,000
158,164,000
162,156,000
161,784,000
164,861,000
164,682,000
154,521,000
156,905,000
165,131,000
168,499,000
171,525,000
178,415,000
181,208,000
180,767,000
188,200,000
195,514,000
211,779,000
216,498,000
250,899,000
258,716,000
260,009,000
256,254,000
255,065,000
253,111,000
253,065,000
259,805,000
270,091,000
279,451,000
285,823,000
287,580,000
302,914,000
297,122,000
290,900,000
288,271,000
293,662,000
302,248,000
302,865,000
306,193,000
316,061,000
315,221,000
307,585,000
311,602,000
319,632,000
321,405,000
337,488,000
343,556,000
310,072,000
300,927,000
293,979,000
300,925,000
307,190,000
298,720,000
298,720,000307,190,000300,925,000293,979,000300,927,000310,072,000343,556,000337,488,000321,405,000319,632,000311,602,000307,585,000315,221,000316,061,000306,193,000302,865,000302,248,000293,662,000288,271,000290,900,000297,122,000302,914,000287,580,000285,823,000279,451,000270,091,000259,805,000253,065,000253,111,000255,065,000256,254,000260,009,000258,716,000250,899,000216,498,000211,779,000195,514,000188,200,000180,767,000181,208,000178,415,000171,525,000168,499,000165,131,000156,905,000154,521,000164,682,000164,861,000161,784,000162,156,000158,164,000156,404,000144,006,000141,693,000137,442,000137,603,000135,814,000135,393,0000125,368,00000
   Common Stock
0
0
6,457,000
0
6,502,000
6,524,000
6,538,000
6,581,000
6,591,000
6,591,000
6,614,000
6,662,000
6,670,000
6,670,000
6,694,000
6,705,000
6,720,000
0
0
0
0
0
0
0
0
0
7,383,000
7,527,000
7,573,000
7,595,000
7,695,000
7,707,000
7,716,000
7,735,000
7,792,000
7,798,000
7,856,000
7,911,000
8,032,000
8,061,000
8,186,000
8,186,000
8,252,000
8,283,000
8,287,000
8,296,000
8,366,000
8,411,000
8,411,000
8,446,000
8,525,000
8,525,000
8,538,000
8,544,000
8,672,000
8,678,000
8,678,000
8,684,000
8,702,000
8,707,000
8,756,000
8,769,000
8,769,0008,756,0008,707,0008,702,0008,684,0008,678,0008,678,0008,672,0008,544,0008,538,0008,525,0008,525,0008,446,0008,411,0008,411,0008,366,0008,296,0008,287,0008,283,0008,252,0008,186,0008,186,0008,061,0008,032,0007,911,0007,856,0007,798,0007,792,0007,735,0007,716,0007,707,0007,695,0007,595,0007,573,0007,527,0007,383,0000000000006,720,0006,705,0006,694,0006,670,0006,670,0006,662,0006,614,0006,591,0006,591,0006,581,0006,538,0006,524,0006,502,00006,457,00000
   Retained Earnings Total Equity00000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
42,807,000
38,309,000
37,781,000
46,975,000
48,679,000
43,674,000
43,674,00048,679,00046,975,00037,781,00038,309,00042,807,00000000000000000000000000000000000000000000000000000000000
   Capital Surplus 00000000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
-2,222,000
0
-512,000
-1,280,000
-1,988,000
-3,366,000
-3,820,000
-3,507,000
2,212,000
2,750,000
2,355,000
1,478,000
2,137,000
2,027,000
-12,850,000
8,288,000
14,130,000
15,831,000
15,425,000
20,033,000
21,093,000
21,049,000
23,115,000
27,430,000
25,556,000
27,549,000
25,374,000
31,905,000
30,369,000
24,663,000
17,132,000
25,503,000
21,855,000
24,948,000
28,975,000
31,320,000
28,566,000
28,729,000
36,412,000
26,532,000
23,989,000
19,701,000
17,923,000
24,045,000
21,077,000
23,764,000
26,007,000
22,217,000
28,303,000
30,353,000
-290,834,000
-289,642,000
-299,149,000
-299,653,000
-3,963,000
4,345,000
9,425,000
-251,368,000
-1,951,000
-6,890,000
-6,890,000-1,951,000-251,368,0009,425,0004,345,000-3,963,000-299,653,000-299,149,000-289,642,000-290,834,00030,353,00028,303,00022,217,00026,007,00023,764,00021,077,00024,045,00017,923,00019,701,00023,989,00026,532,00036,412,00028,729,00028,566,00031,320,00028,975,00024,948,00021,855,00025,503,00017,132,00024,663,00030,369,00031,905,00025,374,00027,549,00025,556,00027,430,00023,115,00021,049,00021,093,00020,033,00015,425,00015,831,00014,130,0008,288,000-12,850,0002,027,0002,137,0001,478,0002,355,0002,750,0002,212,000-3,507,000-3,820,000-3,366,000-1,988,000-1,280,000-512,0000-2,222,00000



Balance Sheet

Currency in JPY. All numbers in thousands.




Cash Flow

Currency in JPY. All numbers in thousands.




Income Statement

Currency in JPY. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue279,037,000
Cost of Revenue-112,950,000
Gross Profit166,087,000166,087,000
 
Operating Income (+$)
Gross Profit166,087,000
Operating Expense-169,177,000
Operating Income-3,090,000-3,090,000
 
Operating Expense (+$)
Research Development28,297,000
Selling General Administrative96,257,000
Selling And Marketing Expenses-
Operating Expense169,177,000124,554,000
 
Net Interest Income (+$)
Interest Income1,153,000
Interest Expense-1,499,000
Other Finance Cost-0
Net Interest Income-346,000
 
Pretax Income (+$)
Operating Income-3,090,000
Net Interest Income-346,000
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-5,799,00038,009,000
EBIT - interestExpense = -5,799,000
-5,764,000
-13,449,000
Interest Expense1,499,000
Earnings Before Interest and Taxes (EBIT)-4,300,000-4,300,000
Earnings Before Interest and Taxes (EBITDA)12,949,000
 
After tax Income (+$)
Income Before Tax-5,799,000
Tax Provision-9,184,000
Net Income From Continuing Ops-14,983,000-14,983,000
Net Income-14,948,000
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses282,127,000
Total Other Income/Expenses Net-41,099,000346,000
 

Technical Analysis of Santen
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Santen. The general trend of Santen is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Santen's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Santen Pharmaceutical Co.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 9.79 < 9.86 < 10.80.

The bearish price targets are: 8.95 > 8.72 > 8.31.

Tweet this
Santen Pharmaceutical Co Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Santen Pharmaceutical Co. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Santen Pharmaceutical Co Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Santen Pharmaceutical Co. The current macd is -0.12758149.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Santen price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Santen. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Santen price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Santen Pharmaceutical Co Daily Moving Average Convergence/Divergence (MACD) ChartSanten Pharmaceutical Co Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Santen Pharmaceutical Co. The current adx is 28.61.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Santen shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Santen Pharmaceutical Co Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Santen Pharmaceutical Co. The current sar is 9.74707016.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Santen Pharmaceutical Co Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Santen Pharmaceutical Co. The current rsi is 47.40. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Santen Pharmaceutical Co Daily Relative Strength Index (RSI) ChartSanten Pharmaceutical Co Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Santen Pharmaceutical Co. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Santen price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Santen Pharmaceutical Co Daily Stochastic Oscillator ChartSanten Pharmaceutical Co Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Santen Pharmaceutical Co. The current cci is -20.68236715.

Santen Pharmaceutical Co Daily Commodity Channel Index (CCI) ChartSanten Pharmaceutical Co Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Santen Pharmaceutical Co. The current cmo is -1.27289126.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Santen Pharmaceutical Co Daily Chande Momentum Oscillator (CMO) ChartSanten Pharmaceutical Co Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Santen Pharmaceutical Co. The current willr is -45.23809524.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Santen is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Santen Pharmaceutical Co Daily Williams %R ChartSanten Pharmaceutical Co Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Santen Pharmaceutical Co.

Santen Pharmaceutical Co Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Santen Pharmaceutical Co. The current atr is 0.22370229.

Santen Pharmaceutical Co Daily Average True Range (ATR) ChartSanten Pharmaceutical Co Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Santen Pharmaceutical Co. The current obv is -1,178,103.

Santen Pharmaceutical Co Daily On-Balance Volume (OBV) ChartSanten Pharmaceutical Co Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Santen Pharmaceutical Co. The current mfi is 53.11.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Santen Pharmaceutical Co Daily Money Flow Index (MFI) ChartSanten Pharmaceutical Co Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Santen Pharmaceutical Co.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-08ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-27MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Santen Pharmaceutical Co Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Santen Pharmaceutical Co based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.400
Ma 20Greater thanMa 509.462
Ma 50Greater thanMa 1009.778
Ma 100Greater thanMa 2009.767
OpenGreater thanClose9.410
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Santen with someone you think should read this too:
  • Are you bullish or bearish on Santen? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Santen? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Santen Pharmaceutical Co

I send you an email if I find something interesting about Santen Pharmaceutical Co.


Comments

How you think about this?

Leave a comment

Stay informed about Santen Pharmaceutical Co.

Receive notifications about Santen Pharmaceutical Co in your mailbox!